The consistent therapeutic benefits observed with diverse Hsp90 inhibitors, such as Geldanamycin, Ganetespib, 17-AAG, and RGRN - 305, administered systemically or topically, provide strong rationale for further clinical evaluation in patients with AD (Table 1). The gene discussed is HSP90AB1; the disease is Alzheimer disease.